Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Control: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Analysis is based on exact Fisher test to compare treatments.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Treatment groups were compared for frequency of allograft nonfunction using Fisher exact test

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Reparixin and Control groups will be compared for degree of allograft steatosis using Cochran-Mantel-Hensel (CMH) test with control EAD.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Reparixin and Control groups will be compared for duration of cold ischemia using Cochran-Mantel-Hensel (CMH) test with control EAD.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Reparixin and Control groups will be compared for duration of earm ischemia using Cochran-Mantel-Hensel (CMH) test with control EAD.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Standard care procedures: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

General survival and graft survival ("graft loss" will be qualified as an event for "graft survival") within 1 year were presented with Kaplan-Mayer curves and survival time median with 95% CI. Treatment groups will be compared using logrank test.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Control: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Control: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.

Patients in the group of the study therapy received Reparixin at dose of 2.772 mg/kg/hour for 7 days (168 hours). The prepared solution of Reparixin 11 mg/ml was administered as a continuous infusion into a central vein using an automatic infusion pump that provides a constant rate of infusion.

Reparixin infusion started 60-90 minutes before OLT. Infusion interruption was allowed for no more than 60 minutes.

All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Reparixin: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours). Infusion of the study drug started approximately 60-90 minutes before the anticipated time of OLT (Orthotopic liver transplantation).The status of patients and allograft survival was monitored up to 1 year after OLT.

The patients, who were randomized in the control group, did not receive any study therapy. All patients of the study received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.

Control: The patients, who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.